Gilead licenses HIV injections for $25m

24-07-2019

Rory O'Neill

Gilead licenses HIV injections for $25m

II Studio / Shutterstock.com

Gilead has obtained exclusive worldwide rights to market a long-acting injectable HIV product based on Durect Corporation’s Saber technology.


Gilead, Durect Corporation, HIV, PReP, pre-exposure prophylaxis, Saber, exclusive, Hepatitis B, Truvada

LSIPR